Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Frequently asked questions
What sector does Resverlogix Corp. (RVXCF) operate in?
Resverlogix Corp. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Resverlogix Corp. (RVXCF) current stock price?
As of the latest data, Resverlogix Corp. stock price is $0.06, with a previous close of $0.06.
What is Resverlogix Corp. (RVXCF) current market capitalization?
Resverlogix Corp. market cap is approximately 20.66 million.
What is Resverlogix Corp. (RVXCF) Earnings Per Share (EPS)?
The trailing EPS is -$0.03.
What is Resverlogix Corp. (RVXCF) EBITDA?
Resverlogix Corp. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.36 million.
Does Resverlogix Corp. (RVXCF) pay dividends?
No. Resverlogix Corp. does not pay a dividend.
What is Resverlogix Corp. (RVXCF) beta (volatility) score?
Resverlogix Corp. has a beta of 1.056, meaning its volatility is roughly in line with the market.